Both the Presence of a Micropapillary Component and the Micropapillary Predominant Subtype Predict Poor Prognosis After Lung Adenocarcinoma Resection: a Meta-analysis

Overview

Journal J Cardiothorac Surg

Publisher Biomed Central

Specialties Cardiology & Vascular Diseases
General Surgery
Pulmonary Medicine

Date 2020 Jul 1

PMID 32600473

Citations 21

Authors

Wei Wang

Zaoxiu Hu

Jie Zhao

Yunchao Huang

Sunyin Rao

Jichen Yang

Shouyong Xiao

Run Cao

Lianhua Ye

Affiliations

Soon will be listed here.

Abstract

Objective: It has been confirmed that the micropapillary (MP) pattern is a poor prognostic factor after resection of lung adenocarcinoma (ADC), but the proportion of the MP component as a prognostic criterion is still controversial. Hence, a meta-analysis was performed to evaluate whether the presence of an MP component has equal prognostic power as the MP predominant subtype.

Methods: Literature retrieval was performed in the MEDLINE, EMBASE, and Cochrane databases until December 23, 2019. Eligible studies were selected based on the inclusion and exclusion criteria. The included studies were divided into two subgroups, the MP component subgroup and the MP predominant subgroup, according to the proportion of the MP pattern to analyse the effect of this pattern on disease-free survival (DFS) and overall survival (OS). The hazard ratio (HR) and 95% confidence interval (CI) were extracted from each study. Review Manager 5.3 was used for statistical analyses.

Results: Finally, 10 studies, including a total of 4934 lung ADC patients, were included in this meta-analysis. Our results indicated a significantly worse pooled DFS (HR 1.62, 95% CI 1.20-2.21) and OS (HR 1.53, 95% CI 1.19-1.96) in the subgroup of MP predominant subtype patients. The pooled DFS (HR 1.80, 95% CI 1.45-2.85) and OS (HR 2.26, 95% CI 1.46-3.52) were also poor in the subgroup of patients with the presence of an MP component.

Conclusions: Both the presence of an MP component and the MP predominant subtype are related to poor DFS and OS after lung ADC resection and represent adverse prognostic factor for lung ADC patients. However, there are some limitations in this meta-analysis, and quantitative stratification based on the proportion of the MP component is needed to explore its effect on prognosis of lung ADC patients in the future.

Citing Articles

Application and progress of non-invasive imaging in predicting lung invasive non-mucinous adenocarcinoma under the new IASLC grading guidelines.

Feng J, Shao X, Gao J, Ge X, Sun Y, Shi Y Insights Imaging. 2025; 16(1):4.

PMID: 39747759 PMC: 11695567. DOI: 10.1186/s13244-024-01877-4.

Predicting prognosis in patients with stage IA lung adenocarcinoma with a micropapillary component using a nomogram based on computed tomography radiomics and clinicopathologic factors: a retrospective analysis.

Li Y, Zhao J, Li R, Yao X, Dong X, Zhao Y Transl Lung Cancer Res. 2024; 13(10):2585-2602.

PMID: 39507031 PMC: 11535836. DOI: 10.21037/tlcr-24-544.

Predicting pathological grade of stage I pulmonary adenocarcinoma: a CT radiomics approach.

Huang X, Xue Y, Deng B, Chen J, Zou J, Tan H Front Oncol. 2024; 14:1406166.

PMID: 39399170 PMC: 11466725. DOI: 10.3389/fonc.2024.1406166.

The impact of postoperative adjuvant therapy on EGFR-mutated stage IA lung adenocarcinoma with micropapillary pathological subtypes.

Cheng R, Hao Z, Qiu L, Zheng X, Huang S, Xian J World J Surg Oncol. 2024; 22(1):235.

PMID: 39232762 PMC: 11375949. DOI: 10.1186/s12957-024-03429-y.

Sublobar resection for lung adenocarcinoma less than 2 cm containing solid or micropapillary components radiologically presented as consolidation-to-tumor ratio (CTR) ≤0.25 [ground-glass opacity (GGO)].

Zhu M, Xu Y, Huang J, Yao Y, Tosi D, Koike T Transl Lung Cancer Res. 2024; 13(7):1685-1694.

PMID: 39118896 PMC: 11304140. DOI: 10.21037/tlcr-24-231.

References

Zhang H, Lu C, Lu Y, Yu B, Lv F, Zhu Z . The predictive and prognostic values of factors associated with visceral pleural involvement in resected lung adenocarcinomas. Onco Targets Ther. 2016; 9:2337-48. PMC: 4844436. DOI: 10.2147/OTT.S100965. View

Lee J, Kim E, Kim M, Shim H . Genetic and clinicopathologic characteristics of lung adenocarcinoma with tumor spread through air spaces. Lung Cancer. 2018; 123:121-126. DOI: 10.1016/j.lungcan.2018.07.020. View

Yi E, Bae M, Cho S, Chung J, Jheon S, Kim K . Pathological prognostic factors of recurrence in early stage lung adenocarcinoma. ANZ J Surg. 2017; 88(4):327-331. DOI: 10.1111/ans.14033. View

Chao L, Yi-Sheng H, Yu C, Li-Xu Y, Xin-Lan L, Dong-Lan L . Relevance of EGFR mutation with micropapillary pattern according to the novel IASLC/ATS/ERS lung adenocarcinoma classification and correlation with prognosis in Chinese patients. Lung Cancer. 2014; 86(2):164-9. DOI: 10.1016/j.lungcan.2014.08.018. View

Song C, Kimura D, Sakai T, Tsushima T, Fukuda I . Novel approach for predicting occult lymph node metastasis in peripheral clinical stage I lung adenocarcinoma. J Thorac Dis. 2019; 11(4):1410-1420. PMC: 6531694. DOI: 10.21037/jtd.2019.03.57. View

Zhao X, Zhang Y, Qian K, Zhao L, Wang W, Teng L . Prognostic significance of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of stage I lung adenocarcinoma: A retrospective study based on analysis of 110 Chinese.... Thorac Cancer. 2017; 8(6):565-571. PMC: 5668519. DOI: 10.1111/1759-7714.12464. View

Qian F, Yang W, Wang R, Xu J, Wang S, Zhang Y . Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma. J Thorac Cardiovasc Surg. 2017; 155(3):1227-1235.e2. DOI: 10.1016/j.jtcvs.2017.09.143. View

Yao S, Zhi X, Wang R, Qian K, Hu M, Zhang Y . Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations. Thorac Cancer. 2016; 7(5):543-548. PMC: 5130296. DOI: 10.1111/1759-7714.12365. View

Warth A, Muley T, Meister M, Stenzinger A, Thomas M, Schirmacher P . The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol. 2012; 30(13):1438-46. DOI: 10.1200/JCO.2011.37.2185. View

10.

Ma M, She Y, Ren Y, Dai C, Zhang L, Xie H . Micropapillary or solid pattern predicts recurrence free survival benefit from adjuvant chemotherapy in patients with stage IB lung adenocarcinoma. J Thorac Dis. 2018; 10(9):5384-5393. PMC: 6196197. DOI: 10.21037/jtd.2018.08.64. View

11.

Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y . Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients--based on a hospital study in China. Eur J Surg Oncol. 2013; 39(11):1262-8. DOI: 10.1016/j.ejso.2013.08.026. View

12.

Hayden J, van der Windt D, Cartwright J, Cote P, Bombardier C . Assessing bias in studies of prognostic factors. Ann Intern Med. 2013; 158(4):280-6. DOI: 10.7326/0003-4819-158-4-201302190-00009. View

13.

Hung J, Wu Y, Chou T, Jeng W, Yeh Y, Hsu W . Adjuvant Chemotherapy Improves the Probability of Freedom From Recurrence in Patients With Resected Stage IB Lung Adenocarcinoma. Ann Thorac Surg. 2016; 101(4):1346-53. DOI: 10.1016/j.athoracsur.2015.10.075. View

14.

Ettinger D, Wood D, Aggarwal C, Aisner D, Akerley W, Bauman J . NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. J Natl Compr Canc Netw. 2019; 17(12):1464-1472. DOI: 10.6004/jnccn.2019.0059. View

15.

Travis W, Brambilla E, Noguchi M, Nicholson A, Geisinger K, Yatabe Y . International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc. 2011; 8(5):381-5. DOI: 10.1513/pats.201107-042ST. View

16.

Sun Y, Yu X, Shi X, Hong W, Zhao J, Shi L . Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients. World J Surg Oncol. 2014; 12:148. PMC: 4067105. DOI: 10.1186/1477-7819-12-148. View

17.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

18.

Westaway D, Toon C, Farzin M, Sioson L, Watson N, Brady P . The International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society grading system has limited prognostic significance in advanced resected pulmonary adenocarcinoma. Pathology. 2013; 45(6):553-8. DOI: 10.1097/PAT.0b013e32836532ae. View

19.

Watanabe Y, Kusumoto M, Yoshida A, Suzuki K, Asamura H, Tsuta K . Surgically resected solitary cavitary lung adenocarcinoma: association between clinical, pathologic, and radiologic findings and prognosis. Ann Thorac Surg. 2015; 99(3):968-74. DOI: 10.1016/j.athoracsur.2014.10.040. View

20.

Postmus P, Kerr K, Oudkerk M, Senan S, Waller D, Vansteenkiste J . Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4):iv1-iv21. DOI: 10.1093/annonc/mdx222. View